<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25300887</PMID>
<DateCompleted>
<Year>2015</Year>
<Month>05</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1471-2407</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>14</Volume>
<PubDate>
<Year>2014</Year>
<Month>Oct</Month>
<Day>09</Day>
</PubDate>
</JournalIssue>
<Title>BMC cancer</Title>
<ISOAbbreviation>BMC Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma.</ArticleTitle>
<Pagination>
<MedlinePgn>752</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-2407-14-752</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Endometrial cancer is the most common gynecologic malignancy. Type II endometrial carcinoma is often poorly differentiated and patients diagnosed with Type II disease (~11%) are disproportionately represented in annual endometrial cancer deaths (48%). Recent genomic studies highlight mutations in chromatin regulators as drivers in Type II endometrial carcinoma tumorigenesis, suggesting the use of epigenetic targeted therapies could provide clinical benefit to these patients. We investigated the anti-tumor efficacy of the LSD1 inhibitor HCI2509 in two poorly differentiated Type II endometrial cancer cell lines AN3CA and KLE.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The effects of HCI2509 on viability, proliferation, anchorage-independent growth, global histone methylation, LSD1 target gene induction, cell cycle, caspase activation and TUNEL were assayed. KLE cells were used in an orthotopic xenograft model to assess the anti-tumor activity of HCI2509.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Both AN3CA and KLE cells were sensitive to HCI2509 treatment with IC50s near 500 nM for cell viability. Inhibition of LSD1 with HCI2509 caused decreased proliferation and anchorage independent growth in soft agar, elevated global histone methylation, and perturbed the cell cycle in both cell lines. These effects were largely dose-dependent. HCI2509 treatment also caused apoptotic cell death. Orthotopic implantation of KLE cells resulted in slow-growing and diffuse tumors throughout the abdomen. Tumor burden was distributed log-normally. Treatment with HCI2509 resulted 5/9 tumor regressions such that treatment and regressions were significantly associated (p=0.034).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings demonstrate the anti-cancer properties of the LSD1 inhibitor HCI2509 on poorly differentiated endometrial carcinoma cell lines, AN3CA and KLE. HCI2509 showed single-agent efficacy in orthotopic xenograft studies. Continued studies are needed to preclinically validate LSD1 inhibition as a therapeutic strategy for endometrial carcinoma.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Theisen</LastName>
<ForeName>Emily R</ForeName>
<Initials>ER</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gajiwala</LastName>
<ForeName>Snehal</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bearss</LastName>
<ForeName>Jared</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sorna</LastName>
<ForeName>Venkataswamy</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sharma</LastName>
<ForeName>Sunil</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Janat-Amsbury</LastName>
<ForeName>Margit</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT, USA. margit.janat-amsbury@hsc.utah.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30 CA042014</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>10</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>BMC Cancer</MedlineTA>
<NlmUniqueID>100967800</NlmUniqueID>
<ISSNLinking>1471-2407</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006657">Histones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.11.-</RegistryNumber>
<NameOfSubstance UI="D056466">Histone Demethylases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.5.-</RegistryNumber>
<NameOfSubstance UI="C495195">KDM1A protein, human</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002471">Cell Transformation, Neoplastic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016889">Endometrial Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056466">Histone Demethylases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006657">Histones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008745">Methylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D060787">Neoplasm Grading</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047368">Tumor Burden</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2014</Year>
<Month>06</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2014</Year>
<Month>09</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2014</Year>
<Month>10</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2014</Year>
<Month>10</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2015</Year>
<Month>5</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">25300887</ArticleId>
<ArticleId IdType="pii">1471-2407-14-752</ArticleId>
<ArticleId IdType="doi">10.1186/1471-2407-14-752</ArticleId>
<ArticleId IdType="pmc">PMC4197342</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Cancer Cell. 2002 May;1(4):393-401</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12086853</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Discov. 2012 May;2(5):405-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22588878</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gynecol Oncol. 1983 Feb;15(1):10-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6822361</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2004 Dec 29;119(7):941-53</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15620353</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gynecol Oncol. 2005 Jun;97(3):755-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15913742</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 2005 Sep 15;437(7057):436-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16079795</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gynecol Oncol. 2005 Oct;99(1):135-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16024066</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2012 Jul 6;150(1):12-27</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22770212</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hum Pathol. 2012 Aug;43(8):1300-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22245111</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 2012 Dec;32(23):4861-76</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23028048</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Genet. 2012 Dec;44(12):1310-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23104009</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>World J Gastroenterol. 2012 Dec 7;18(45):6651-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23236241</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Protoc Pharmacol. 2012 Dec;Chapter 14:Unit 14.22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23258598</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gynecol Oncol. 2013 Feb;128(2):344-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22871469</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23359684</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Gynecol Cancer. 2013 Jul;23(6):997-1005</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23792601</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2013 Oct 17;32(42):5089-100</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23178492</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 2014 Jan;34(2):158-79</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24190971</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Chem. 2014 Jan;60(1):98-110</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24170611</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Med Chem. 2013 Dec 12;56(23):9496-508</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24237195</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2014 Sep 1;20(17):4584-97</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24963049</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2006 Dec 1;66(23):11341-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17145880</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gynecol Oncol. 2007 May;105(2):493-500</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17303224</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 2007 May 25;282(21):15471-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17409384</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Cancer. 2008 Jul 1;123(1):8-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18425818</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Carcinog. 2008 Sep;47(9):701-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18176935</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Control. 2009 Jan;16(1):46-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19078929</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2009 Mar 1;69(5):2065-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19223552</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19474385</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2009 Aug 14;325(5942):834-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19608861</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2009 Aug 21;138(4):660-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19703393</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Pathol. 2009 Sep;62(9):777-85</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18977806</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Carcinogenesis. 2010 Jan;31(1):27-36</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19752007</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Carcinogenesis. 2010 Mar;31(3):512-20</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20042638</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hum Pathol. 2010 Jun;41(6):848-58</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20178884</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2010 Sep 2;29(35):4896-904</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20562920</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hum Pathol. 2010 Nov;41(11):1516-29</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20800872</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Cancer. 2011 Feb 1;128(3):574-86</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20333681</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Reprod Biol Endocrinol. 2010;8:147</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21122138</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2011 Feb 1;71(3):655-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21115810</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2011 Feb 1;10(3):413-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21270517</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Cancer. 2010 Dec 15;127(12):2893-917</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21351269</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Epigenetics. 2010 Aug 16;5(6):491-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20543579</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Struct Mol Biol. 2011 Aug;18(8):867-74</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21725293</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hum Pathol. 2011 Nov;42(11):1667-75</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21531005</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22237781</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Cell. 2012 Apr 17;21(4):473-87</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22464800</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Cell Sci. 2003 Jun 1;116(Pt 11):2117-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12730288</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>